MedTrace Logo

Lung Clearance Index to Identify Scleroderma Patients at Risk for ILD

NCT04535245 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-03-24

No results posted yet for this study

Summary

This National Jewish Health (NJH) Investigator Initiated pilot study funded by the Shah Foundation will prospectively perform a non invasive lung function test called Lung Clearance Index (LCI) to determine if 50 scleroderma patients without evidence of lung disease who have evidence of small airway inflammation or impairment to airflow are more likely to develop ILD than those with normal vales.50 subjects will be enrolled from the Rheumatology practice at NJH and followed with phone interviews or Electronic Medical Record (EMR) record review yearly times 5 to determine if they have subsequently developed evidence of ILD or pulmonary artery hypertension.

Conditions

  • Scleroderma

Interventions

DIAGNOSTIC_TEST

LCI testing

all subjects will have LCI testing then contacted via a phone interview or EMR review yearly times 5 to determine if they have subsequently developed ILD

Sponsors & Collaborators

  • National Jewish Health

    lead OTHER

Principal Investigators

  • Richard T Meehan, MD · National Jewish Health

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-04
Primary Completion
2026-01-15
Completion
2026-01-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04535245 on ClinicalTrials.gov